North America

By Richard Y. Cheung, Ph.D., Toronto, Fasken Martineau DuMoulin

Due to concerns about the growing percentage of the health care budget allotted to drug spending in Canada and the relative drug prices in Canada compared to other developed countries, the Canadian government is proposing changes to the way in which prices for patented drugs are regulated …

Read or download the full article below.

Tags: Canada, Life Sciences
Latest Updates
Related Articles
Related Articles by Jurisdiction
Canada: No Duty to Consult Triggered by Omnibus Changes to Environmental Laws
In Canada (Governor General In Council) v. Courtoreille, 2016 FCA 311, the Federal Court of Appeal found that the federal government did not owe a duty to consult when it developed and implemented changes to environmental legislation through two omnibus bills ...
Global Developments on Best Execution
Currently a hot topic for global regulators, firms are recommended to review their global best execution compliance practices ...
Canada: Intellectual Property Bulletin
The New Patented Medicines (Notice of Compliance) Regulations and Certificate of Supplementary Protection Regulations ...
Latest Articles